Global RNAi Drug Pipeline Analysis
“Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. Research report covers all the ongoing drugs being developed in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the RNAi technology associated with the various diseases.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the RNAi Drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Global RNAi Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Orphan Designation by Indication, Country & Organisation
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 26
- Phase-I: 88
- Phase-I/II: 5
- Phase-II: 10
- Phase-III: 1
1.1 Current Market Scenario
1.2 Key Drivers for Adopting RNAi
1.3 Future Opportunity
2. RNAI DRUG DEVELOPMENT PHASE: RESEARCH
2.1 Overview
2.2 RNAi Drug Profile in Development Phase
3. RNAI DRUG DEVELOPMENT PHASE: PRECLINICAL
3.1 Overview
3.2 RNAi Drug Profile in Development Phase
4. RNAI DRUG DEVELOPMENT PHASE: PHASE-I
4.1 Overview
4.2 RNAi Drug Profile in Development Phase
5. RNAI DRUG DEVELOPMENT PHASE: PHASE:I/II
5.1 Overview
5.2 RNAi Drug Profile in Development Phase
6. RNAI DRUG DEVELOPMENT PHASE: PHASE-II
6.1 Overview
6.2 RNAi Drug Profile in Development Phase
7. RNAI DRUG DEVELOPMENT PHASE: PHASE-III
7.1 Overview
7.2 RNAi Drug Profile in Development Phase
The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.
The global market for RNAi was estimated to be close to USD xx billion in 2010. This market is expected to record a significant growth rate of approximately 27.9% and rapidly reach USD xx billion by 2017. The major factors contributing to such rapid and high growth of RNAi include the increasing adoption rate of RNAi technology in the functional genomics research industry. This technology is being increasingly used for drug development, discovery and validation of therapeutic targets. Additionally, in recent years the application of this technology has expanded to agricultural and plant research also, which collectively would drive the RNAi market on the growth trajectory.
Among the various regions, US and Europe account for the largest share of the global pie of RNAi market, with US being the single largest market. The European region expected to increase at a CAGR of close to xx% up to 2017. Among the end-use sectors of RNAi, the most dominant application of RNAi has been drug discovery and target validation, followed by RNAi reagents. The share of the reagents segment is expected to increase significantly as this segment is most likely to grow at a rapid rate of xx% through 2017.
Following the approval of the cholesterol-lowering mipomersen of Isis Pharmaceuticals in January 2013, the RNA therapeutics industry has become an attractive investment option for scientists and investors.
Hence, many private and public companies have concentrated their activities on developing RNA-based technologies in order to capture this enormous potential to reach multiple end markets and regions.
